Zusammenfassung
Die WHO-Klassifikation der Tumoren der Mamma bildet international die Basis für die Einordnung und Nomenklatur der Tumoren. Die 2012 erschienene 4. Auflage spiegelt unser gegenwärtiges Verständnis zur Klassifikation, Immunhistologie, Differenzialdiagnose und Genetik der Läsionen wider. Verglichen mit der 3. Auflage enthält sie einige Änderungen in der Terminologie. Etablierte Entitäten wurden neu bewertet und zahlreiche molekulare Aspekte wurden hinzugefügt. Dieser Beitrag behandelt die invasiven Karzinome. Die histopathologischen Definitionen der aktuellen WHO-Klassifikation werden durch die Beschreibungen der klinischen, makroskopischen, molekularen sowie prognostischen und prädiktiven Eigenschaften der Tumoren ergänzt.
Abstract
The World Health Organization (WHO) classification of tumors of the breast defines the international standards for tumor categorization and nomenclature. The fourth edition, published in 2012, provides an update on the current knowledge concerning the classification, immunohistology profile, differential diagnosis and genetics of these lesions. Compared to the previous edition, some terms have been modified, some entities were reclassified and some current molecular data have been added. This article focuses on invasive carcinomas. Definitions for histological diagnosis are supplemented by clinical, macroscopic and molecular characteristics as well as prognostic and predictive features.
Literatur
Abati AD, Kimmel M, Rosen PP (1990) Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol 94:371–377
Capella C, Eusebi V, Mann B, Azzopardi JG (1980) Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 4:613–630
Colleoni M, Rotmensz N, Maisonneuve P et al (2011) Outcome of special types of luminal breast cancer. Ann Oncol 23:1428–1436
Eheman CR, Shaw KM, Ryerson AB et al (2009) The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004. Cancer Epidemiol Biomarkers Prev 18:1763–1769
Ellis IO, Galea M, Broughton N et al (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow- up. Histopathology 20:479–489
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71:2507–2514
Kreienberg R, Albert US, Follmann M et al (2012) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. In: Kreienberg R (Hrsg) Leitlinienprogramm Onkologie, 3. Aufl. Zuckschwerdt, München
Lakhani S, Ellis I, Schnitt S et al (2012) WHO classification of tumours of the breast, 4. Aufl. IARC Press, Lyon
Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180
Lee H, Jung SY, Ro JY et al (2012) Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol 65:441–446
Miremadi A, Pinder S, Lee A et al (2002) Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 40:215–222
Niemeier LA, Dabbs DJ et al (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23:205–212
Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113:1511–1520
Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26:3006–3014
Rakha EA, Aleskandarany M, El-Sayed ME et al (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787
Rakha EA, Ellis IO (2007) An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol 60:1300–1306
Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44:73–83
Rody A, Karn T, Liedtke C et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97
Schnitt SJ, Abner A, Gelman R et al (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast- conserving surgery and radiation therapy. Cancer 74:1746–1751
Shin SJ, Rosen PP (2002) Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. Am J Surg Pathol 26:413–420
Sinn HP, Anton HW, Magener A et al (1998) Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34:646–653
Sinn H-P, Helmchen B, Heil J et al (2014) Lobuläre Neoplasie und invasives lobuläres Mammakarzinom. Pathologe. doi: 10.1007/s00292-013-1840-8
Slanger TE, Chang-Claude JC, Obi N et al (2009) Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 18:1188–1196
Talman ML, Jensen MB, Rank F (2007) Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol 46:803–809
Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon
Toikkanen S, Kujari H (1989) Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 20:758–764
Weigelt B, Geyer FC, Horlings HM et al (2009) Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 22(11):1401–1414
Weigelt B, Horlings HM, Kreike B et al (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216:141–150
Wetterskog D, Lopez-Garcia MA, Lambros MB et al (2012) Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 226:84–96
WHO (1981) Histological typing of breast tumours. International histological classification of tumours No. 2. Springer, Berlin Heidelberg New York
Einhaltung ethischer Richtlinien
Interessenkonflikt A. Lebeau, M. Kriegsmann, E. Burandt, H.-P. Sinn geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lebeau, A., Kriegsmann, M., Burandt, E. et al. Invasive Mammakarzinome: Die aktuelle WHO-Klassifikation. Pathologe 35, 7–17 (2014). https://doi.org/10.1007/s00292-013-1841-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-013-1841-7